Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
1999-05-06
2001-02-27
Prats, Francisco (Department: 1651)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
Reexamination Certificate
active
06193975
ABSTRACT:
The invention relates to a new use of an extract of
Potentilla erecta
in the field of cosmetics or pharmacy, especially in dermatology.
Tormentilla or
Potentilla erecta
Raeusch or
Potentilla tormentilla
Stokes or Neck is traditionally used in phytomedicine as an astringent, an anti-diarrhoea or as an anti-allergic. For this, see the work by Bisset “Herbal drugs and phytopharmaceuticals” CRC Press Ed, Boca Raton, USA, 1994, p. 499-501, as well as the book entitled: “A modem herbal” Penguin Handbooks, Harmards worth, England, 1980, p. 819-820.
Tormentilla is also a cultivated plant, in particular in central Russia in particular in Ural and is therefore easily accessible as has been described by Vasfilova E. S. and Ivanova G. A., Rastit. Resur 1989, 25, 67-73.
Bos et al., in the review Biological and Pharmaceutical Bulletin, 1996, 19, 146-148, have recently described an anti-lipoperoxidising and antielastasic activity of procyanidines extracted from tormentilla.
German patent DE 3911185 also describes the use of an extract of
Potentilla erecta
against bad breath.
Japanese patent application JP 01121221 of Daiso Co describes the use of an aqueous or organic extract of the same plant for treating diabetes, this extract having aldose reductase inhibiting properties.
A publication by Selemina L V., Zozulga R. N., Yakovleva T. N. in Rastit. Resur. 1973, 9, 409-414, describes the anti-inflammatory properties and those of an extract of the roots of tormentilla which improve the reinforcement of the walls of blood capillaries.
Other works have described the use of tannins of
Potentilla erecta
as anti-allergic agents and immunostimulants (Lund et al. Deutsche Apothekr Zeitung, 1985, 125, 105-108).
Furthermore, it is known that collagen of type VII, hereinafter designated as collagen VII, is the main constituent of the anchoring fibrils which are combined with the basal membrane, linking the epidermis to the dermis. It is synthesised by the keratinocytes of the basal layer of the epidermis, and in a lesser amount, by the fibroblasts of the dermis, as described by R.Burgeson in a publication entitled: “Type VII collagen, anchoring fibrils, and epidermolysis bullosa”, J. Invest. Dermatol, (1993) 101,252-255. It will also be possible to refer to the publication of A. Koenig et al, in J. Invest. Dermatol. (1992) 99 808-812. As regards this, it will be noted that according to recent studies, topical applications of retinoic acid increased the number of anchoring fibrils on skins having undergone an actinic ageing (Woodley D. T. et al., J. Amer. Med. Assoc. (1990) 263, 3057-9). Retinoic acid, or tretinoin, is recognised as being one of the most efficient anti-wrinkle agents (L. H. Kligman, Cutis (1988) 41 (6) 419-20; J. J. Leyden et al, J. Am. Acad. Dermatol. (1989) 21 (3Pt 2) 638-44; J. H. Saurat, Horm. Res. (1995) 43 (1-3) 89-92).
According to the publication of Y. Q. Chen, A. Mauviel, J. Ryynanen, S. Sollberg, J. Uitto (“Type VII collagen gene expression by human skin fibroblasts and keratinocytes in culture: Influence of donor age and cytokine responses” J. Invest. Dermatol, (1994) 102, 205-209), certain manifestations of skin ageing, such as an increased skin fragility and a decrease in the capacities of repair of the epidermis, might be attributable to a reduction of the synthesis of collagen VII in aged subjects. It will be noted that the expression <<skin fragility>> in particular covers the appearance of sub-basal blisters.
Finally, it has been described by M. Akiyama et al. in J. Invest. Dermatol. (1995) 105 844-850, that collagen, collagen VII in particular, played an important role at the level of the human hair follicle, notably at the level of the basal membranes of the matrix (peripapillary zone) and at the level of the basal membrane of the bulge (bulge of the upper part of the bulb). These two areas contain cells having high mitotic potential, in particular keratinocytes giving rise to the hair stem. These authors indicated that the collagen VII present in the follicle is indispensable for the expression of this mitotic activity.
The authors of the present invention have now demonstrated, in an entirely surprising way, that an extract of
Potentilla erecta
has an effect upon the secretion of collagen VII by normal human keratinocytes.
This observation has led to the development of novel cosmetic or pharmaceutical compositions, notably dermatological compositions, which are more particularly useful in any application in which it is sought to stimulate the synthesis of collagen VII.
This property has proved to be particularly useful for the preparation of topical cosmetic or dermatological compositions. Such compositions in particular enable promoting the cohesion between the dermis and the epidermis in persons having a loosened or dull skin. The compositions have also proved to be useful for hair cares which are intended for improving hair condition. The compositions also enable treating pathologies which accompany a deficiency of the dermo-epidermal junction, such as epidermolysis bullosa.
Thus, according to one of its essential characteristics, the invention relates to the use of an extract of the plant
Potentilla erecta
as cosmetic agent intended for improving the cohesion between the dermis and the epidermis by reinforcing the dermo-epidermal junction, said agent being incorporated in a cosmetic composition comprising a cosmetically acceptable vehicle.
It has been clearly demonstrated that the extract incorporated in the composition acts by stimulating the formation of collagen VII, and this constitutes another essential characteristic of the invention.
Thus, the compositions of the invention prove to be particularly useful in any application in which it is sought to improve the cohesion between the dermis and the epidermis.
The composition will in particular be intended to obtain a toning of the skin, to prevent or to delay the appearance of signs of skin ageing, to delay the appearance of wrinkles or to decrease their depth, to improve hair condition.
It can be an anti-wrinkles product, a product intended for fighting against skin ageing and loosening of the skin or it can be a hair care lotion.
The cosmetic compositions of the invention prove to be particularly interesting for fighting against skin ageing, in particular against actinic ageing of the skin, i.e. ageing induced by radiation, solar radiation in particular, more particularly ultraviolet solar radiation.
Generally, the cosmetic compositions of the invention prove to be particularly useful as a product for toning the skin which is intended, in particular, for fighting against loose or dull skins.
According to another of its essential characteristics, the invention also relates to the use of an extract of the plant
Potentilla erecta
for preparing a pharmaceutical composition, notably a dermatological composition, intended for treating pathologies linked to a deficiency in the cohesion between the dermis and the epidermis, in particular those linked to a weakening of the dermo-epidermal junction.
The pharmaceutical compositions, notably dermatological compositions of the invention, will in particular find application in the treatment of manifestations or pathologies linked to an insufficiency in the formation of collagen VII.
Epidermolysis bullosa will in particular be cited as an example of such pathologies.
It will be possible for the dermatological compositions of the invention to be also advantageously used as a healing composition in the treatment of wounds, optionally as a supplement to local therapeutic treatments, in particular for improving the quality of the skin before and after healing.
It will be possible for various solvents to be used for obtaining an extract of the plant used in accordance with the present invention. However, water, a C
1
to C
4
alcohol, a C
2
to C
6
glycol, or any mixture of the solvents mentioned above will advantageously be selected, in particular an aqueous alcohol mixture or aqueous glycol mixture. Of course, the extraction solvent is selected su
Bonte Frederic
Chaudagne Catherine
Dumas Marc
Meybeck Alain
Coe Susan D.
LVMH Recherche
Nath Gary M.
Nath & Associates
Prats Francisco
LandOfFree
Use of potentilla erecta extract in the cosmetic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of potentilla erecta extract in the cosmetic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of potentilla erecta extract in the cosmetic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2567914